Catalent, Inc.

NYSE:CTLT Stock Report

Market Cap: US$11.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Catalent Valuation

Is CTLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CTLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CTLT ($63.48) is trading below our estimate of fair value ($64.1)

Significantly Below Fair Value: CTLT is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTLT?

Key metric: As CTLT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CTLT. This is calculated by dividing CTLT's market cap by their current revenue.
What is CTLT's PS Ratio?
PS Ratio2.6x
SalesUS$4.42b
Market CapUS$11.52b

Price to Sales Ratio vs Peers

How does CTLT's PS Ratio compare to its peers?

The above table shows the PS ratio for CTLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
RPRX Royalty Pharma
4.9x7.2%US$14.7b
VTRS Viatris
1x-1.1%US$14.9b
TEVA Teva Pharmaceutical Industries
1.5x2.7%US$25.1b
ELAN Elanco Animal Health
1.3x3.8%US$5.7b
CTLT Catalent
2.6x6.8%US$11.5b

Price-To-Sales vs Peers: CTLT is expensive based on its Price-To-Sales Ratio (2.6x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does CTLT's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

69 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x0.02%US$3.75b
PRGO Perrigo
0.8x3.4%US$3.51b
BHC Bausch Health Companies
0.3x1.5%US$2.75b
AMRX Amneal Pharmaceuticals
0.9x5.6%US$2.41b
CTLT 2.6xIndustry Avg. 3.0xNo. of Companies69PS03.67.210.814.418+
69 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CTLT is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is CTLT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTLT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ratio3.6x

Price-To-Sales vs Fair Ratio: CTLT is good value based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CTLT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$63.48
US$63.43
-0.08%
0.3%US$63.50US$63.00n/a7
Dec ’25US$61.11
US$63.43
+3.8%
0.3%US$63.50US$63.00n/a7
Nov ’25US$58.73
US$63.43
+8.0%
0.3%US$63.50US$63.00n/a7
Oct ’25US$60.23
US$63.43
+5.3%
0.3%US$63.50US$63.00n/a7
Sep ’25US$60.96
US$63.43
+4.0%
0.3%US$63.50US$63.00n/a7
Aug ’25US$59.78
US$63.43
+6.1%
0.3%US$63.50US$63.00n/a7
Jul ’25US$56.16
US$63.43
+12.9%
0.3%US$63.50US$63.00n/a7
Feb ’25US$53.09
US$50.49
-4.9%
14.3%US$65.00US$40.00n/a13
Jan ’25US$44.93
US$49.29
+9.7%
14.2%US$65.00US$40.00n/a14
Dec ’24US$40.15
US$49.29
+22.8%
14.2%US$65.00US$40.00US$61.1114
Nov ’24US$32.18
US$51.36
+59.6%
11.4%US$65.00US$44.00US$58.7314
Oct ’24US$45.53
US$51.64
+13.4%
10.9%US$65.00US$44.00US$60.2314
Sep ’24US$50.20
US$52.00
+3.6%
10.9%US$65.00US$44.00US$60.9614
Aug ’24US$46.51
US$50.79
+9.2%
23.8%US$86.00US$37.00US$59.7814
Jul ’24US$43.36
US$50.77
+17.1%
25.4%US$86.00US$33.00US$56.1613
Jun ’24US$37.00
US$48.23
+30.4%
30.8%US$86.00US$28.00US$53.7913
May ’24US$50.12
US$68.33
+36.3%
23.5%US$90.00US$40.00US$56.0012
Apr ’24US$65.71
US$84.09
+28.0%
4.4%US$90.00US$78.00US$56.3911
Mar ’24US$69.01
US$83.92
+21.6%
4.3%US$90.00US$78.00US$57.1912
Feb ’24US$54.72
US$74.09
+35.4%
18.1%US$100.00US$58.00US$53.0911
Jan ’24US$45.01
US$74.73
+66.0%
18.5%US$100.00US$60.00US$44.9311
Dec ’23US$52.23
US$76.00
+45.5%
17.5%US$100.00US$60.00US$40.1512

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 09:28
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Catalent, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Sel HardyCFRA Equity Research
Parth TalsaniaEquisights